DE60313657D1 - Antivirale zusammensetzungen - Google Patents

Antivirale zusammensetzungen

Info

Publication number
DE60313657D1
DE60313657D1 DE60313657T DE60313657T DE60313657D1 DE 60313657 D1 DE60313657 D1 DE 60313657D1 DE 60313657 T DE60313657 T DE 60313657T DE 60313657 T DE60313657 T DE 60313657T DE 60313657 D1 DE60313657 D1 DE 60313657D1
Authority
DE
Germany
Prior art keywords
antiviral compositions
antiviral
compositions
oxathiolan
deoxythymidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313657T
Other languages
English (en)
Other versions
DE60313657T2 (de
Inventor
Gary Wayne Goodson
Alison Green Floyd
Cecilia Carpenter Navy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
SmithKline Beecham Corp
Original Assignee
Glaxo Group Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, SmithKline Beecham Corp filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60313657D1 publication Critical patent/DE60313657D1/de
Publication of DE60313657T2 publication Critical patent/DE60313657T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60313657T 2002-11-08 2003-11-07 Antivirale zusammensetzungen Expired - Lifetime DE60313657T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42518202P 2002-11-08 2002-11-08
US425182P 2002-11-08
PCT/US2003/035830 WO2004043433A2 (en) 2002-11-08 2003-11-07 Pharmaceutical antiviral compositions

Publications (2)

Publication Number Publication Date
DE60313657D1 true DE60313657D1 (de) 2007-06-14
DE60313657T2 DE60313657T2 (de) 2008-01-03

Family

ID=32312939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313657T Expired - Lifetime DE60313657T2 (de) 2002-11-08 2003-11-07 Antivirale zusammensetzungen

Country Status (9)

Country Link
US (1) US20050287177A1 (de)
EP (1) EP1567133B1 (de)
JP (1) JP2006508134A (de)
AT (1) ATE361059T1 (de)
AU (1) AU2003291457A1 (de)
CA (1) CA2505130C (de)
DE (1) DE60313657T2 (de)
ES (1) ES2286471T3 (de)
WO (1) WO2004043433A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1658068B1 (de) 2003-08-26 2009-02-18 Smithkline Beecham Corporation Cycloalkyl[b] kondensierte indole
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
RU2008128424A (ru) * 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CA2686964A1 (en) * 2007-06-06 2008-12-11 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
US20100184785A1 (en) * 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
US20100178340A1 (en) * 2007-06-22 2010-07-15 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
WO2010137855A2 (en) * 2009-05-27 2010-12-02 Dasan Medichem Co., Ltd. Multi-layer tablet comprising effervescent layer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
CZ285232B6 (cs) * 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US6177435B1 (en) * 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US5681581A (en) * 1992-08-04 1997-10-28 Dunn; James M. Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof

Also Published As

Publication number Publication date
EP1567133B1 (de) 2007-05-02
EP1567133A2 (de) 2005-08-31
AU2003291457A1 (en) 2004-06-03
WO2004043433A3 (en) 2004-12-29
CA2505130C (en) 2009-10-06
CA2505130A1 (en) 2004-05-27
JP2006508134A (ja) 2006-03-09
US20050287177A1 (en) 2005-12-29
DE60313657T2 (de) 2008-01-03
ES2286471T3 (es) 2007-12-01
WO2004043433A2 (en) 2004-05-27
AU2003291457A8 (en) 2004-06-03
ATE361059T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
TW366346B (en) 1,3-oxathiolane nucleoside analogue
EA199700203A1 (ru) Синергические комбинации зидовудина, 1592u89 и 3тс или ftc
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
PL398295A1 (pl) Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania
AU2003291726A8 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
TW366347B (en) Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues
UY26615A1 (es) Inhibidor de la glucogeno fosforilasa.
EP1720556A4 (de) Neue 2'-c-methyl-nucleosid-derivate
DE60313657D1 (de) Antivirale zusammensetzungen
FR2880626B1 (fr) Derives de la purine, compositions les contenant et utilisation
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
UY24930A1 (es) Composiciones farmaceuticas que contienen (2r, cis)-4-amino-1-(2-hidroximetil-1,3 -oxatiolan-5-il)-(1h)-pirimidin-2-ona (lamivudina)
YU58398A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use the terapy of hiv
NO20065791L (no) Asyklovir-formuleringer
MEP34308A (en) Oral formulations of cladribine
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
JP2006508134A5 (de)
TW200509794A (en) Novel anthelmintic and insecticidal compositions
BRPI0417513A (pt) agentes combinados de chp-gemcitabina e seu uso como substáncias antitumorais ativas
WO2001030329A3 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction
UY27628A1 (es) "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco"
WO2000018383A3 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
ECSP982450A (es) Composiciones farmaceuticas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition